RxDoctor Payments Data

James Calmes, MD

Rheumatology · Lubbock, TXNPI 1750363057

Payments from drug & device makers

$110,345in general payments, 2019–2025

Across 448 payments — averaging $246.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$91K
  • Regeneron$13K
  • Amgen$2K
  • AbbVie$2K
  • UCB, Inc.$943
  • GSK$234
  • plus $899 from 15 others

What the payments were for

  • Food & beverage$5,847100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$110,345 in reported general payments places this provider in the 80th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$1,468,930
Medicare patients
496
Services billed
78,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab97$884,825
Enbrel SureclickEtanercept76$741,652
RinvoqUpadacitinib43$268,606
Cosentyx Sensoready PenSecukinumab26$204,664
XeljanzTofacitinib Citrate19$134,289
EnbrelEtanercept17$121,962
Orencia ClickjectAbatacept13$111,791
Teriparatide22$49,238
Hydroxychloroquine Sulfate508$13,919
MethotrexateMethotrexate Sodium562$12,813
Mycophenolate Mofetil45$5,795
Gabapentin370$4,085
Pilocarpine Hcl60$3,938
Prednisone509$3,823
Duloxetine Hcl160$2,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,588$268,60643 claims
PfizerXeljanz$91,093$134,28919 claims
AmgenEnbrel$2,110$121,96217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →